Summary

From the substance class of benzene-fused cycloalkylamines arise at least two therapeutically valuable substances which irreversibly inhibit MAO-A and MAO-B more or less selectively. These include rasagiline (10a) and ladostigil (12), which are said to have neuroprotective properties. They also counteract neurodegenerative diseases. A number of rigid analogs (e.g. 1, 3, 19, 20, 34) were tested for the ability to inhibit the enzyme PNMT. Its inhibition prevents epinephrine synthesis in the CNS. The pharmacological benefit of this inhibition has not yet been clarified. Compared to amphetamine, 2-AT (20) showed 50 times stronger inhibitory properties. Some substances were investigated as rigid analogues of amphetamine (e.g. 2-Al; 14, 2-AT; 20, 2-ADN; 25), with all derivatives being less effective in vivo (drug discrimination study, locomotion).

Literature

[1] J. B. Van der Schoot, E. J. Ariens, J. Van Rossum, J. A. Hurkmanns. Arzneim. Forsch.
    1962, 12, 902.
[2] R. A. Glennon, R. Young, A. E. Hauck, J. D. McKenney. Pharmacol. Biochem. Behav.
    1984, 21, 895.
[3] C. L. Border, D. J. Craik, B. P. Shehan. Magn. Res. Chem. 1993, 31, 222.
[4] S. Sun, E. R. Bernstein. J. A. Soc. 1996, 118, 5086.
[5] G. L. Grunewald, K. M. Markovich, D. J. Sall. J. Med. Chem. 1987, 30, 2191.
[6] R. Okazaki, M. Ooka, N. Tokitoh, N. Inamoto. J. Org. Chem. 1985, 50, 180.
[7] R. W. Fuller, B. W. Roush, S. K. Hemrick, H. D. Snoddy, B. B. Molloy. Life Sci. 1978,
    22,1421.
[8] D.L. Wong, A. Lesage, B. Siddall, J. W. Funder. FASEB J. 1992, 6, 3310.
[9] C. L. Gee, N. Drinkwater, J. D. Tyndall, G. L. Grunewald, Q. Wu, M. J. McLeish, J.
    L. Martin. J. Med. Chem. 2007, 50, 4845.
[10] J. A. Skorcz, J. E. Robertson. J. Med. Chem. 1965, 8, 255.
[11] R.F. Jenny, K. Schenker. Verfahren zur Herstellung von neuen Cyclobutenderivaten.
     CH485647, 1970.
[12] A.S. Horn, S. H. Snyder. J. Pharm. Exp. Ther. 1972, 180, 523.
[13] C. F. Heubner, E. M. Donoghue, A.J. Plummer, P. A. Furness. J. Med. Chem. 1966, 9,
     830.
[14] D. Steinhilber, M, Schubert-Zsilavecz, H. J. Roth. Medizinische Chemie: Targets und
     Arzneistoffe. Deutscher Apotheker Verlag: Stuttgart, D, 2005.
[15] S. Mandel, O. Weinreb, T. Amit, M. B. Youdim. Brain Res. Brain Res. Rev. 2005, 48,
     379.
[16] S. Tazik, S. Johnson, D. Lu, C, Johnson, M. B. Youdim, C. A. Stockmeier, X. M. Ou.
     Neurotox. Res. 2009, 15, 284.
[17] US Food and Drug Administration. FDA Approves the First Treatment for
     Dementia of Parkinson's Disease. http://www.fda.gov/NewsEvents/Newsroom/
     PressAnnouncements/2006/ucm108680.htm
